| PLX Healthcare Services (Schweiz) GmbH - Lenalidomide PLX Healthcare Services 5 mg, Hartkapseln | | 70462 | | 02 | | Lenalidomide PLX Healthcare Services 5 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 04.06.2026 | | |
| | Composition | | lenalidomidum 5 mg ut lenalidomidum ammonii chloridum, lactosum 39.368 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium max. 0.22 mg, magnesii stearas, Kapselhülle: E 171, gelatina, Drucktinte: lacca, E 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | Principe actif | Concentr. |
|---|
| Lenalidomidum | 5 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Nigrum) | | | | Ammoniae Solutio Concentrata | | | | Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | E 171 | | Kapselhülle | | E 172 | | color. | | Gelatina | | | | Kalii Hydroxidum | | | | Lacca | | Drucktinte | | Lactosum | 39.368 mg | | | Magnesii Stearas | | | | Pro Capsula | | | | Propylenglycol | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | 21 | | | A | | Oui |
|
|
